Taking rapamycin, even in small doses now and then, might increase the chance of getting serious infections like pneumonia in older people because it can weaken the immune system.
Evidence from Studies
Supporting (1)
Community contributions welcome
Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA‐EX‐01 Randomised, Double‐Blind, Placebo‐Controlled Trial
The study gave older adults a weekly dose of rapamycin and found one case of pneumonia that might be linked to the drug, which supports the idea that even low doses could increase infection risk.
Contradicting (2)
Community contributions welcome
Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results
The study looked at low-dose rapamycin in older adults and found no more serious side effects, including infections, than in people taking a placebo.
The study looked at low-dose rapamycin in older adults but didn’t track infections, so we can’t tell if it increases infection risk or not.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.